Herpetic encephalitis: which treatment for which body weight?

Area of Science:

• Neurology
• Infectious Diseases
• Pharmacology

Background:

• Herpetic encephalitis carries a severe prognosis with high mortality and sequelae.
• Current acyclovir treatment protocols lack established optimal dosing strategies.
• Determining precise and effective acyclovir administration is critical for improving patient outcomes.

Purpose of the Study:

• To establish optimal acyclovir treatment modalities for herpetic encephalitis.
• To identify factors influencing patient outcomes in herpetic encephalitis.
• To guide clinical management of acyclovir therapy.

Main Methods:

• A retrospective, monocentric study of 76 patients with confirmed herpetic encephalitis (2000-2019).
• Inclusion criteria: age ≥16, clinical/imaging/EEG findings, and positive CSF HSV-PCR.
• Analysis compared clinical data and administered acyclovir doses with patient outcomes.

Main Results:

• Mortality rate was 12%, with 49% complete recovery and 39% sequelae.
• Poor outcomes linked to prolonged confusion, aphasia, impaired consciousness, superinfection, status epilepticus, and ICU stay.
• A decision tree identified patient weight and average daily acyclovir dose as key outcome predictors.

Conclusions:

• Acyclovir management in herpetic encephalitis should be adjusted based on patient weight.
• Low-weight patients (<79 kg) should receive a minimum daily acyclovir dose of 2550 mg (850 mg every 8 hours).
• Optimized acyclovir dosing can potentially improve recovery rates and reduce long-term sequelae.